Compounding HRT Solutions for Female Sexual Dysfunction Patients

According to NAMS (The Menopause Society) and ACOG, in female sexual dysfunction, low sexual desire may present as a persistent or recurrent reduction in interest in sexual activity, with fewer spontaneous sexual thoughts or fantasies, reduced initiation of sexual contact, and diminished responsiveness to sexual cues. According to NIH MedlinePlus, this pattern — sometimes diagnosed as hypoactive sexual desire disorder (HSDD) when accompanied by personal distress — may reflect hormonal shifts, psychological factors, relationship dynamics, or medication effects. Patients experiencing significant distress associated with reduced desire should seek evaluation from a qualified clinician, as sudden changes in desire alongside mood disturbance or physical symptoms may indicate an underlying medical or endocrine condition requiring assessment.

According to NAMS (The Menopause Society) and ACOG, difficulty becoming physically aroused in female sexual dysfunction may present as a persistent or recurrent inability to attain or maintain adequate vaginal lubrication, genital swelling, or physiological response sufficient for sexual activity, despite adequate sexual stimulation. According to NIH MedlinePlus, this may reflect reduced genital blood flow, hormonal changes — particularly declining estrogen around menopause — neuropathic factors, or vascular conditions. Patients experiencing significant arousal difficulty, particularly when accompanied by pain, pelvic symptoms, or cardiovascular risk factors, should seek evaluation from a qualified clinician, as these presentations may indicate conditions requiring clinical assessment and management.

According to ACOG and NAMS (The Menopause Society), in female sexual dysfunction, difficulty reaching orgasm may present as a persistent or recurrent delay in, marked infrequency of, or absence of orgasm following sufficient sexual stimulation, and may be lifelong or acquired, situational or generalized. According to NIH MedlinePlus, this presentation may coexist with hormonal changes, mood disorders, pelvic floor dysfunction, certain medications, or prior pelvic surgery, and is clinically significant when it causes marked personal distress or interpersonal difficulty. Patients experiencing this symptom pattern should seek evaluation from a qualified clinician; symptoms accompanied by pelvic pain, significant mood changes, or recent medication changes may indicate contributors requiring clinical attention.

According to ACOG and NAMS (The Menopause Society), pain during sexual activity — clinically referred to as dyspareunia or, when involving involuntary pelvic floor muscle contraction, vaginismus — is a recurring or persistent discomfort occurring with arousal, penetration, deep thrusting, or orgasm in female sexual dysfunction. According to NIH MedlinePlus, sensations may vary and may include sharp, burning, aching, cramping, or pressure-type pain localized at the vaginal opening, deep pelvic region, urethra, or diffuse across the pelvis. Patients experiencing dyspareunia should seek evaluation from a qualified clinician; sudden, severe, or new-onset pelvic pain may indicate conditions such as infection, endometriosis, or pelvic inflammatory disease requiring urgent medical assessment.

According to the FDA-approved prescribing information for Flibanserin, Flibanserin is a serotonin 1A receptor agonist and serotonin 2A receptor antagonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The labeling describes a mechanism involving modulation of serotonin and dopamine signaling in the central nervous system. Per the labeling, Flibanserin carries a Boxed Warning: due to the risk of severe hypotension and syncope, use with alcohol is contraindicated, and use with moderate or strong CYP3A4 inhibitors is contraindicated; Flibanserin is available only through a Risk Evaluation and Mitigation Strategy (REMS) program. Per the labeling, common adverse reactions may include dizziness, somnolence, nausea, and fatigue; dosing is 100 mg orally once daily at bedtime. Any compounded preparation involving Flibanserin is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Flibanserin products are separately regulated, and clinical decisions belong with the prescribing clinician.

According to the FDA-approved prescribing information for vaginal estrogen products (including estradiol vaginal cream, estradiol vaginal inserts, and estradiol vaginal rings), these locally applied estrogen preparations are indicated for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause, including symptoms of genitourinary syndrome of menopause (GSM) such as vaginal dryness, dyspareunia, and urogenital symptoms. The labeling describes a mechanism involving local estrogenic effects on vaginal epithelium, with low systemic absorption reported at recommended doses for certain formulations. Per the labeling for estrogen-containing products, a Boxed Warning applies: estrogens have been reported to increase the risk of endometrial cancer; estrogens should not be used for the prevention of cardiovascular disease or dementia; and the labeling notes reported risks including stroke, deep vein thrombosis, and pulmonary embolism. Per the labeling, use in patients with known or suspected estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, or a history of certain thromboembolic events may be contraindicated. Any compounded preparation involving vaginal estrogen is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available vaginal estrogen products are separately regulated, and clinical decisions belong with the prescribing clinician.